OverviewChartNewsTraderScreen

UBS Knock-Out LLY/  DE000UL9P985  /

Frankfurt Zert./UBS
2024-11-14  3:54:41 PM Chg.-1.810 Bid4:44:50 PM Ask4:44:50 PM Underlying Strike price Expiration date Option type
18.510EUR -8.91% 18.350
Bid Size: 5,000		 18.440
Ask Size: 5,000		 Eli Lilly and Co 605.5211 USD 2078-12-31 Call
TeleTrader 10-30 Eli Lilly's Q3 revenue up 20% to $11.4 billion
TeleTrader 10-02 Eli Lilly to commit $4.5 billion in a new Indiana facility
Newsfile Corp 09-16 Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer
TeleTrader 09-09 Eli Lilly appoints Lucas Montarce as CFO
Newsfile Corp 08-28 The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire 08-27 Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...
GlobeNewswire 08-26 Eliem Therapeutics Announces Additions to its Leadership Team
GlobeNewswire 08-21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 08-21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 08-14 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire 08-14 Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...
GlobeNewswire 08-08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08-08 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
TeleTrader 08-08 US opens higher with data, earnings in focus
GlobeNewswire 08-08 ProQR Announces Second Quarter 2024 Operating and Financial Results
TeleTrader 08-08 Eli Lilly's Q2 revenue jumps 36% to $11.3B
GlobeNewswire 08-08 Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly
GlobeNewswire 08-07 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire 08-06 Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire 08-06 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...
GlobeNewswire 08-02 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...
GlobeNewswire 08-01 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire 08-01 COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
GlobeNewswire 08-01 Compass Pathways announces second quarter 2024 financial results and business highlights
GlobeNewswire 07-31 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFC, HMNF, MORF on Behalf of Shareholders